Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

OKUROnKure Therapeutics, Inc.

Nasdaq · CIK 0001637715
Filer category<br>Emerging growth company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts251

Identity from submissions API

NameOnKure Therapeutics, Inc.
CIK0001637715
TickersOKUR
ExchangesNasdaq
Entity typeoperating
Category<br>Emerging growth company
SIC2834 Pharmaceutical Preparations
EIN472309515
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(720) 307-2892
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • Reneo Pharmaceuticals, Inc. (2018-01-08T00:00:00.000Z → 2024-10-02T00:00:00.000Z)
Business address
6707 WINCHESTER CIRCLE, SUITE 400
BOULDER
CO
80301
CO
Mailing address
6707 WINCHESTER CIRCLE, SUITE 400
BOULDER
CO
80301
CO

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

No Financialist filing articles yet for this CIK.

SEC filings

406 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-20 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001231919-26-001621 005-92480 261580227 34 35075
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-003184 005-92480 261561364 34 25354
2026-11-04 8-K 8-K 2.02,9.01 0001193125-26-447247 001-40315 261522265 34 406998 1 1
2026-11-04 10-Q 10-Q 0001193125-26-447202 001-40315 261522079 34 9476507 1 1
2026-10-07 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-114447 005-92480 261448039 34 25306
2026-09-23 4 xslF345X06/form4-09232026_080903.xml 0001609284-26-000005 5911
2026-09-23 4 xslF345X06/form4-09232026_080937.xml 0001692747-26-000005 5910
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-097335 005-92480 261283428 34 13784
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-002177 005-92480 261281914 34 25009
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001493152-26-038382 005-92480 261281868 34 11964
2026-08-13 4/A xslF345X06/form4a-08132026_080853.xml 0001622769-26-000006 5558
2026-08-13 8-K 8-K 5.02,9.01 0001193125-26-347315 001-40315 261269184 34 158454 1 1
2026-08-11 4 4 0001193125-26-344874 5497
2026-08-11 4 xslF345X06/form4-08112026_080842.xml 0001547100-26-000005 5786
2026-08-11 4 xslF345X06/form4-08112026_080848.xml 0001921956-26-000003 5804
2026-08-11 4 xslF345X06/form4-08112026_080858.xml 0001622769-26-000002 11801
2026-08-11 4 xslF345X06/form4-08112026_080824.xml 0001889716-26-000002 5807
2026-08-11 4 xslF345X06/form4-08112026_080811.xml 0001240122-26-000006 5782
2026-08-11 4 xslF345X06/form4-08112026_080808.xml 0001644467-26-000002 5760
2026-08-11 4 xslF345X06/form4-08112026_080840.xml 0001609284-26-000004 29642
2026-08-11 4 xslF345X06/form4-08112026_080837.xml 0001692747-26-000004 20922
2026-08-11 4 xslF345X06/form4-08112026_080827.xml 0002037442-26-000002 11799
2026-08-11 4 xslF345X06/form4-08112026_080820.xml 0001748961-26-000002 16407
2026-08-10 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001617201-26-000003 005-92480 261256417 34 15454
2026-08-04 424B5 424B5 0001193125-26-332839 333-291334 261238892 33 29440
2026-08-04 8-K 8-K 2.02,9.01 0001193125-26-332809 001-40315 261238723 34 400257 1 1
2026-08-04 10-Q 10-Q 0001193125-26-332773 001-40315 261238546 34 8364893 1 1
2026-06-24 4 xslF345X06/form4-06242026_110612.xml 0001609284-26-000003 6091
2026-06-24 4 xslF345X06/form4-06242026_110637.xml 0001692747-26-000003 6090
2026-06-08 4 4 0001193125-26-262279 5494
2026-06-08 4 xslF345X06/form4-06082026_100623.xml 0001547100-26-000004 5783
2026-06-08 4 xslF345X06/form4-06082026_100605.xml 0001921956-26-000002 5801
2026-06-08 4 xslF345X06/form4-06082026_100613.xml 0001889716-26-000001 5804
2026-06-08 4 xslF345X06/form4-06082026_100628.xml 0001240122-26-000003 5779
2026-06-08 4 xslF345X06/form4-06082026_100629.xml 0001644467-26-000001 5757
2026-06-05 S-8 S-8 0001193125-26-259599 333-296544 261069268 33 478224 1 1
2026-06-04 8-K 8-K 5.02,5.07,9.01 0001193125-26-257423 001-40315 261065151 34 456111 1 1
2026-05-27 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-001486 005-92480 261026833 34 39690
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-062876 005-92480 26990444 34 13480
2026-05-05 8-K 8-K 2.02,9.01 0001193125-26-206396 001-40315 26943158 34 361106 1 1
2026-05-05 10-Q 10-Q 0001193125-26-206345 001-40315 26942962 34 6948003 1 1
2026-05-04 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-001477 333-295304 26940141 33 1843
2026-04-30 CORRESP filename1.htm 0001193125-26-197156 9436
2026-04-30 UPLOAD filename1.pdf 0000000000-26-004422 333-295304 149225
2026-04-24 S-3 S-3 0001193125-26-177093 333-295304 26893508 33 1201926 1 1
2026-04-21 DEFA14A DEFA14A 0001140361-26-015904 001-40315 26879641 34 2106677
2026-04-21 DEF 14A DEF 14A 0001140361-26-015903 001-40315 26879624 34 5039376 1 1
2026-04-21 ARS ARS 0001193125-26-166821 001-40315 26879594 34 1401070
2026-04-07 3 3 0001193125-26-146027 28501
2026-04-07 SCHEDULE 13D xslSCHEDULE_13D_X02/primary_doc.xml 0001193125-26-146025 005-92480 26846276 34 286486
2026-04-07 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-145912 005-92480 26846115 34 298001
2026-04-07 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001493152-26-015540 005-92480 26845336 34 24914
2026-04-07 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001346824-26-000096 005-92480 26845072 34 20023
2026-04-03 4 xslF345X06/form4-04032026_070404.xml 0001609284-26-000002 5745
2026-04-03 4 xslF345X06/form4-04032026_070438.xml 0001692747-26-000002 5743
2026-04-03 4 xslF345X06/form4-04032026_070422.xml 0002037442-26-000001 5731
2026-04-03 4 xslF345X06/form4-04032026_070420.xml 0001748961-26-000001 5685
2026-04-01 4 xslF345X06/form4-04012026_090435.xml 0001547100-26-000003 5726
2026-04-01 3 xslF345X06/form3-04012026_090406.xml 0001547100-26-000002 8835
2026-04-01 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001636587-26-000021 005-92480 26825742 34 14706
2026-03-30 8-K 8-K 1.01,3.02,5.02,8.01,9.01 0001193125-26-130283 001-40315 26809751 34 633313 1 1
2026-03-24 4 xslF345X06/form4-03242026_100353.xml 0001609284-26-000001 5911
2026-03-24 4 xslF345X06/form4-03242026_100303.xml 0001692747-26-000001 5911
2026-03-12 S-8 S-8 0001193125-26-104215 333-294248 26748101 33 365340 1 1
2026-03-12 10-K 10-K 0001193125-26-104147 001-40315 26747791 34 12444607 1 1
2026-03-12 8-K 8-K 2.02,9.01 0001193125-26-104104 001-40315 26747623 34 367558 1 1
2026-02-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-016660 005-92480 26644800 34 19283
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-016541 005-92480 26643056 34 18329
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-26-001088 005-92480 26641237 34 9302
2026-01-30 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000102909-26-000240 005-92480 26582428 34 7156
2026-01-02 4 4 0001193125-26-000942 4824
2026-01-02 4 xslF345X05/form4-01022026_090120.xml 0001622769-26-000001 5101
2025-12-23 4 xslF345X05/form4-12242025_011243.xml 0001609284-25-000004 5962
2025-12-23 4 xslF345X05/form4-12242025_011233.xml 0001692747-25-000004 5940
2025-11-28 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-116660 005-92480 251532420 34 36256
2025-11-21 424B3 424B3 0001193125-25-291362 333-282792 251508012 33 223889
2025-11-18 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-003308 333-282792 251496550 33 1857
2025-11-06 POS AM POS AM 0001193125-25-270150 333-282792 251459676 33 292312
2025-11-06 S-3 S-3 0001193125-25-270073 333-291334 251459492 33 1211150 1 1
2025-11-06 424B3 424B3 0001193125-25-269724 333-282792 251458930 33 3214187
2025-11-06 8-K 8-K 1.01,9.01 0001193125-25-269652 001-40315 251458728 34 684789 1 1
2025-11-06 10-Q 10-Q 0001193125-25-269540 001-40315 251458421 34 8058467 1 1
2025-11-06 8-K 8-K 2.02,9.01 0001193125-25-269468 001-40315 251458198 34 397196 1 1
2025-10-02 4 4 0001193125-25-228402 4828
2025-10-02 4 xslF345X05/form4-10022025_081020.xml 0001622769-25-000003 5102
2025-09-24 4 xslF345X05/form4-09242025_110912.xml 0001609284-25-000003 5774
2025-09-24 4 xslF345X05/form4-09242025_110914.xml 0001692747-25-000003 5774
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-021974 005-92480 251221220 34 11315
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-109073 005-92480 251221084 34 9925
2025-08-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003640 005-92480 251219002 34 9105
2025-08-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-25-076638 005-92480 251218714 34 26036
2025-08-12 10-Q 10-Q 0001193125-25-178981 001-40315 251207034 34 7940424 1 1
2025-08-12 8-K 8-K 2.02,9.01 0001193125-25-178978 001-40315 251207029 34 394154 1 1
2025-08-12 424B3 424B3 0001193125-25-178979 333-282792 251207025 33 2646465
2025-07-02 4 4 0000950170-25-093063 4840
2025-07-02 4 xslF345X05/form4-07022025_080710.xml 0001415889-25-019052 5101
2025-06-26 8-K 8-K 7.01,9.01 0000950170-25-090403 001-40315 251080545 34 9830212 1 1
2025-06-25 4 xslF345X05/form4-06252025_100613.xml 0001415889-25-018235 5773
2025-06-25 4 xslF345X05/form4-06252025_100636.xml 0001415889-25-018234 5773
2025-05-30 4 4 0000950170-25-079841 5373
2025-05-30 4 xslF345X05/form4-05302025_080528.xml 0001415889-25-015019 5664
2025-05-30 4 xslF345X05/form4-05302025_080518.xml 0001415889-25-015018 5640
2025-05-30 4 xslF345X05/form4-05302025_080515.xml 0001415889-25-015016 5667
2025-05-30 4 xslF345X05/form4-05302025_080510.xml 0001415889-25-015015 10662
2025-05-30 4 xslF345X05/form4-05302025_080501.xml 0001415889-25-015014 5620
2025-05-30 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001636587-25-000030 005-92480 251010628 34 150550
2025-05-29 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001723643-25-000011 005-92480 251004003 34 11799 1 1
2025-05-28 424B3 424B3 0000950170-25-078388 333-282792 25995902 33 92910
2025-05-28 8-K 8-K 5.07,9.01 0000950170-25-078375 001-40315 25995794 34 173476 1 1
2025-05-27 3 3 0000950170-25-078004 6285
2025-05-22 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0001636587-25-000027 005-92480 25977937 34 150259
2025-05-19 4 xslF345X05/form4.xml 0000929638-25-001950 14417
2025-05-19 4 4 0000950170-25-074459 10797
2025-05-19 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-002418 005-92480 25963494 34 10356
2025-05-14 4 xslF345X05/form4.xml 0000929638-25-001870 14541
2025-05-06 424B3 424B3 0000950170-25-063972 333-282792 25915279 33 2381496
2025-05-06 10-Q 10-Q 0000950170-25-063970 001-40315 25915270 34 7246042 1 1
2025-05-06 8-K 8-K 2.02,9.01 0000950170-25-063969 001-40315 25915260 34 406853 1 1
2025-04-16 DEFA14A DEFA14A 0001140361-25-014186 001-40315 25843128 34 3929461
2025-04-16 DEF 14A DEF 14A 0001140361-25-014183 001-40315 25843085 34 4268813 1 1
2025-04-16 ARS ARS 0000950170-25-054752 001-40315 25843059 34 1673334
2025-04-08 4 xslF345X05/form4-04082025_090410.xml 0001415889-25-010419 7807
2025-04-08 4 xslF345X05/form4-04082025_090445.xml 0001415889-25-010418 7809
2025-04-02 4 4 0000950170-25-049473 4839
2025-04-02 4 xslF345X05/form4-04022025_080441.xml 0001415889-25-009659 5100
2025-03-24 424B3 424B3 0001193125-25-061340 333-282792 25764174 33 3142332
2025-03-21 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000731 333-282792 25762109 33 1856
2025-03-20 POS AM POS AM 0001193125-25-058954 333-282792 25756367 33 9874508 1 1
2025-03-10 S-8 S-8 0000950170-25-036363 333-285680 25724218 33 207528
2025-03-10 424B3 424B3 0000950170-25-036341 333-282792 25724071 33 8128236
2025-03-10 8-K 8-K 2.02,9.01 0000950170-25-036306 001-40315 25723866 34 391713 1 1
2025-03-10 10-K 10-K 0000950170-25-036252 001-40315 25723670 34 18920824 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-000885 005-92480 25623568 34 11483
2025-02-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-000772 005-92480 25601932 34 9291
2025-02-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-003306 005-92480 25598990 34 10405
2025-01-31 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000246 005-92480 25576353 34 6230
2025-01-29 4 xslF345X05/form4-01302025_010119.xml 0001415889-25-002312 5621
2025-01-29 4 xslF345X05/form4-01302025_010107.xml 0001415889-25-002311 5616
2025-01-29 4 xslF345X05/form4-01302025_010153.xml 0001415889-25-002310 5604
2025-01-29 4 xslF345X05/form4-01302025_010108.xml 0001415889-25-002309 5558
2025-01-21 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001104659-25-004963 005-92480 25543573 34 29550
2024-12-10 424B3 424B3 0000950170-24-134758 333-282792 241537122 33 12643849
2024-12-10 8-K 8-K 7.01,8.01,9.01 0000950170-24-134757 001-40315 241537121 34 10718832 1 1
2024-12-09 S-8 S-8 0000950170-24-134582 333-283693 241535494 33 317555
2024-11-14 SC 13G/A AMENDMENT NO. 1 0001214659-24-019110 005-92480 241461364 34 104584
2024-11-14 SC 13G ONKURE THERAPEUTICS, INC. 0000902664-24-006543 005-92480 241458128 34 49023
2024-11-07 424B3 424B3 0000950170-24-123367 333-282792 241435949 33 3301226
2024-11-07 8-K 8-K 4.01,8.01,9.01 0000950170-24-123265 001-40315 241435489 34 1746999 1 1
2024-11-07 10-Q 10-Q 0000950170-24-123233 001-40315 241435337 34 6645694 1 1
2024-10-31 424B3 424B3 0001193125-24-248666 333-282792 241415274 33 4641839
2024-10-30 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2024-10-30 16:30:00 9999999995-24-003323 333-282792 241412151 33 1851
2024-10-28 CORRESP filename1.htm 0001193125-24-245562 6656
2024-10-28 SC 13G/A AMENDMENT NO. 1 0001214659-24-017999 005-92480 241400853 34 69615
2024-10-25 UPLOAD filename1.pdf 0000000000-24-011951 333-282792 40161
2024-10-23 S-1 S-1 0001193125-24-241926 333-282792 241389745 33 17959118 1 1
2024-10-23 SC 13G/A deeptrack-okur100424a1.htm 0001172661-24-004335 005-92480 241389404 34 103842
2024-10-21 D xslFormDX01/primary_doc.xml 06b 0001748961-24-000002 021-527340 241383009 33 16406
2024-10-16 SC 13G/A sc13g.htm 0000929638-24-003523 005-92480 241374969 34 191940
2024-10-15 3 xslF345X02/form3.xml 0000929638-24-003520 13889
2024-10-11 SC 13G SC 13G 0001104659-24-108113 005-92480 241368280 34 149481
2024-10-11 SC 13G sc13g.htm 0000929638-24-003493 005-92480 241367806 34 220170
2024-10-11 SC 13G SC 13G 0001104659-24-108050 005-92480 241367726 34 93306
2024-10-11 SC 13G deeptrack-okur100424.htm 0001172661-24-004242 005-92480 241367514 34 103203
2024-10-10 SC 13G SC 13G 0001193125-24-236085 005-92480 241366070 34 64100
2024-10-10 SC 13D/A SC 13D/A 0001193125-24-235952 005-92480 241365556 34 203094
2024-10-09 3 3 0000950170-24-113744 7800
2024-10-09 SC 13G SC 13G 0001193125-24-235212 005-92480 241362797 34 79263
2024-10-09 SC 13G/A bml13g.htm 0001373604-24-000102 005-92480 241361944 34 75340
2024-10-09 4 xslF345X05/form4.xml 0001373604-24-000100 8351
2024-10-08 SC 13D/A NEW ENTERPRISE ASSOCIATES 15, L.P. / ONKURE THERAPEUTICS, INC. -- SCHEDULE 13D/A 0001072613-24-000769 005-92480 241361265 34 116938
2024-10-08 4 xslF345X05/form4-10082024_111041.xml 0001415889-24-024921 19331
2024-10-08 4 xslF345X05/form4-10082024_111029.xml 0001415889-24-024920 5599
2024-10-08 4 4 0000950170-24-113604 5308
2024-10-08 4 xslF345X05/form4-10082024_111032.xml 0001415889-24-024919 5575
2024-10-08 4 xslF345X05/form4-10082024_111036.xml 0001415889-24-024918 14919
2024-10-08 4 xslF345X05/form4-10082024_111035.xml 0001415889-24-024917 5602
2024-10-08 4 xslF345X05/form4-10082024_111042.xml 0001415889-24-024914 5657
2024-10-08 4 xslF345X05/form4-10082024_111039.xml 0001415889-24-024913 5556
2024-10-08 4 xslF345X05/form4-10082024_111033.xml 0001415889-24-024912 16058
2024-10-08 4 xslF345X05/form4-10082024_111019.xml 0001415889-24-024911 9677
2024-10-08 3 xslF345X02/form3-10082024_111024.xml 0001415889-24-024910 8488
2024-10-08 3 xslF345X02/form3-10082024_111046.xml 0001415889-24-024909 8471
2024-10-08 3 xslF345X02/form3-10082024_111047.xml 0001415889-24-024908 8439
2024-10-08 3 xslF345X02/form3-10082024_111044.xml 0001415889-24-024907 8478
2024-10-08 3 xslF345X02/form3-10082024_111049.xml 0001415889-24-024906 8478
2024-10-08 3 xslF345X02/form3-10082024_111004.xml 0001415889-24-024905 8464
2024-10-08 3 xslF345X02/form3-10082024_111048.xml 0001415889-24-024904 8439
2024-10-08 3 xslF345X02/form3-10082024_111007.xml 0001415889-24-024903 8420
2024-10-08 8-K 8-K 2.01,3.02,3.03,5.01,5.02,5.03,5.05,5.06,7.01,9.01 0001193125-24-234487 001-40315 241361006 34 3148509 1 1
2024-10-02 425 425 0001193125-24-231283 001-40315 241348874 34 36440
2024-10-02 8-K 8-K 5.07 0001193125-24-231281 001-40315 241348836 34 173775 1 1
2024-09-26 SC 13G r925240sc13g.htm 0001214659-24-016774 005-92480 241328778 34 112375
2024-09-26 4 xslF345X05/form4.xml 0001373604-24-000098 7817
2024-09-20 425 425 0001193125-24-222435 001-40315 241311668 34 90864
2024-09-20 8-K 8-K 8.01 0001193125-24-222429 001-40315 241311664 34 252714 1 1
2024-09-19 4 xslF345X05/form4.xml 0001373604-24-000094 7810
2024-09-16 4 xslF345X05/form4.xml 0001373604-24-000090 9726
2024-09-13 8-K 8-K 5.02 0001193125-24-218879 001-40315 241298031 34 148431 1 1
2024-08-26 EFFECT xslEFFECTX01/primary_doc.xml S-4,,2024-08-26 16:30:00 9999999995-24-002630 333-280369 241243102 33 1771
2024-08-26 424B3 424B3 0001193125-24-207172 333-280369 241242238 33 8022767
2024-08-26 S-4/A S-4/A 0001193125-24-206641 333-280369 241237704 33 8121562
2024-08-23 CORRESP filename1.htm 0001193125-24-206283 8595
2024-08-19 CORRESP filename1.htm 0001193125-24-202441 17767
2024-08-19 S-4/A S-4/A 0001193125-24-202432 333-280369 241218188 33 8367058
2024-08-14 4 xslF345X05/form4.xml 0001373604-24-000071 7847
2024-08-13 10-Q 10-Q 0000950170-24-096411 001-40315 241202743 34 6493648 1 1
2024-08-13 425 425 0000950170-24-096146 001-40315 241201285 34 342891
2024-08-13 8-K 8-K 2.02,9.01 0000950170-24-096127 001-40315 241201176 34 495950 1 1
2024-08-12 UPLOAD filename1.pdf 0000000000-24-009213 333-280369 63842
2024-07-29 S-4/A S-4/A 0001193125-24-186500 333-280369 241148627 33 7791602
2024-07-26 CORRESP filename1.htm 0001193125-24-186501 65031
2024-07-18 UPLOAD filename1.pdf 0000000000-24-008170 333-280369 81670
2024-06-21 S-4 S-4 0001193125-24-164731 333-280369 241057843 33 7265945
2024-05-21 SC 13G/A bml13g.htm 0001373604-24-000032 005-92480 24967352 34 77981
2024-05-16 4 xslF345X05/form4.xml 0001373604-24-000028 7837
2024-05-16 3 xslF345X02/form3.xml 0001373604-24-000026 4769
2024-05-13 425 425 0001193125-24-136811 001-40315 24937215 34 13466900
2024-05-13 8-K 8-K 1.01,3.02,5.01,5.02,7.01,9.01 0001193125-24-136785 001-40315 24937137 34 14131956 1 1
2024-05-08 SC 13D/A NEW ENTERPRISE ASSOCIATES 15, L.P. / RENEO PHARMA -- SCHEDULE 13D/A(#1) 0001072613-24-000437 005-92480 24926771 34 315756
2024-05-07 10-Q 10-Q 0000950170-24-054452 001-40315 24921703 34 5915770 1 1
2024-05-07 8-K 8-K 2.02,9.01 0000950170-24-054442 001-40315 24921615 34 405370 1 1
2024-04-26 10-K/A 10-K/A 0000950170-24-048631 001-40315 24878452 34 1032187 1 1
2024-03-28 S-8 S-8 0000950170-24-038022 333-278315 24798817 33 185237
2024-03-28 10-K 10-K 0000950170-24-038009 001-40315 24798690 34 8324833 1 1
2024-03-28 8-K 8-K 2.02,9.01 0000950170-24-038003 001-40315 24798650 34 422619 1 1
2024-02-23 8-K 8-K 2.05 0000950170-24-019338 001-40315 24670997 34 171228 1 1
2024-02-05 SC 13G j15240sc13g.htm 0001214659-24-001920 005-92480 24595638 34 66900
2024-01-17 SC 13G bml13g.htm 0001616824-24-000011 005-92480 24536269 34 78143
2023-12-26 SC 13D o1226230sc13d.htm 0001214659-23-016861 005-92480 231513876 34 118080
2023-12-15 SC 13D/A SC 13D/A 0001193125-23-296752 005-92480 231491121 34 67929
2023-12-14 8-K 8-K 2.05,8.01 0001193125-23-295039 001-40315 231485784 34 153566 1 1
2023-11-21 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-11-21 16:30:00 9999999995-23-003413 333-275518 231429869 33 1722
2023-11-17 CORRESP filename1.htm 0001193125-23-279781 6324
2023-11-16 UPLOAD filename1.pdf 0000000000-23-012582 40302
2023-11-13 S-3 S-3 0001193125-23-276182 333-275518 231399958 33 963252
2023-11-13 424B5 424B5 0001193125-23-276153 333-264616 231399791 33 503331
2023-11-13 10-Q 10-Q 0000950170-23-062910 001-40315 231398588 34 8207989 1 1
2023-11-13 8-K 8-K 2.02,9.01 0000950170-23-062888 001-40315 231398369 34 537343 1 1
2023-10-30 8-K 8-K 8.01 0000950170-23-056416 001-40315 231360949 34 175661 1 1
2023-10-10 8-K 8-K 7.01,8.01,9.01 0001193125-23-252984 001-40315 231315429 34 15892062 1 1
2023-08-29 4 FORM 4 SUBMISSION 0001209191-23-047626 9344
2023-08-28 144 xsl144X01/primary_doc.xml 0001972362-23-000714 001-40315 231217364 33 4158
2023-08-10 10-Q 10-Q 0000950170-23-041302 001-40315 231159319 34 7876223 1 1
2023-08-10 8-K 8-K 2.02,9.01 0000950170-23-041275 001-40315 231159144 34 587721 1 1
2023-07-27 4 FORM 4 SUBMISSION 0001209191-23-043558 6669
2023-06-23 4 FORM 4 SUBMISSION 0001209191-23-039541 5325
2023-06-23 144 xsl144X01/primary_doc.xml 0001842612-23-000014 001-40315 231039114 33 4500
2023-06-13 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-06-13 16:30:00 9999999995-23-001742 333-272421 231012870 33 1722
2023-06-09 CORRESP filename1.htm 0001193125-23-164445 5595
2023-06-08 4 FORM 4 SUBMISSION 0001209191-23-035585 5400
2023-06-08 4 FORM 4 SUBMISSION 0001209191-23-035566 5408
2023-06-08 4 FORM 4 SUBMISSION 0001209191-23-035565 5499
2023-06-08 4 FORM 4 SUBMISSION 0001209191-23-035564 8496
2023-06-08 4 FORM 4 SUBMISSION 0001209191-23-035563 8485
2023-06-08 4 FORM 4 SUBMISSION 0001209191-23-035562 5452
2023-06-08 4 FORM 4 SUBMISSION 0001209191-23-035560 8507
2023-06-08 4 FORM 4 SUBMISSION 0001209191-23-035557 8450
2023-06-08 UPLOAD filename1.pdf 0000000000-23-006159 40259
2023-06-07 8-K 8-K 5.07 0000950170-23-026807 001-40315 23998948 34 217049 1 1
2023-06-05 S-3 S-3 0001193125-23-160692 333-272421 23992509 33 206880
2023-05-30 SC 13D/A SC 13D/A 0001193125-23-156675 005-92480 23977326 34 239574
2023-05-15 SC 13D/A SC 13D/A 0001193125-23-145205 005-92480 23924335 34 66027
2023-05-11 10-Q 10-Q 0000950170-23-021234 001-40315 23911110 34 7044653 1 1
2023-05-11 8-K 8-K 2.02,9.01 0000950170-23-021217 001-40315 23910991 34 528205 1 1
2023-05-10 4 FORM 4 SUBMISSION 0001209191-23-028533 5570
2023-05-09 SC 13D/A SC 13D/A 0001193125-23-139466 005-92480 23902649 34 197114
2023-05-05 8-K 8-K 1.01,3.02,8.01,9.01 0001193125-23-137165 001-40315 23894425 34 829419 1 1
2023-05-04 424B5 424B5 0001193125-23-136090 333-264616 23889965 33 623308
2023-05-03 424B5 424B5 0001193125-23-134428 333-264616 23884308 33 628005
2023-05-03 8-K 8-K 2.02,7.01,8.01,9.01 0001193125-23-134386 001-40315 23883576 34 6546104 1 1
2023-04-26 ARS ARS 0000950170-23-014812 001-40315 23849919 34 7398196
2023-04-26 DEFA14A DEFA14A 0000950170-23-014803 001-40315 23849820 34 2094850
2023-04-26 DEF 14A DEF 14A 0000950170-23-014792 001-40315 23849743 34 2473023
2023-03-27 S-8 S-8 0000950170-23-010044 333-270878 23765167 33 255490
2023-03-27 10-K 10-K 0000950170-23-009978 001-40315 23764521 34 16945627 1 1
2023-03-27 8-K 8-K 2.02,9.01 0000950170-23-009977 001-40315 23764493 34 794748 1 1
2023-03-14 8-K 8-K 8.01 0000950170-23-007709 001-40315 23729186 34 171650 1 1
2023-03-10 8-K 8-K 7.01 0001193125-23-067520 001-40315 23723359 34 150216 1 1
2023-01-09 8-K 8-K 7.01,9.01 0001193125-23-004092 001-40315 23516458 34 5692772 1 1
2022-12-13 4 FORM 4 SUBMISSION 0001209191-22-061044 6367
2022-12-13 4 FORM 4 SUBMISSION 0001209191-22-061038 9424
2022-12-13 4 FORM 4 SUBMISSION 0001209191-22-061034 9371
2022-12-13 4 FORM 4 SUBMISSION 0001209191-22-061032 10151
2022-12-13 4 FORM 4 SUBMISSION 0001209191-22-061031 7176
2022-11-08 10-Q 10-Q 0000950170-22-023250 001-40315 221369200 34 8448566 1 1
2022-11-08 8-K 8-K 2.02,9.01 0000950170-22-023234 001-40315 221369137 34 817572 1 1
2022-09-30 SC 13D/A SC 13D/A 0001193125-22-255621 005-92480 221284643 34 62103
2022-09-02 4 FORM 4 SUBMISSION 0001209191-22-048534 5829
2022-09-02 4 FORM 4 SUBMISSION 0001209191-22-048532 11537
2022-08-31 4 FORM 4 SUBMISSION 0001209191-22-048167 15675
2022-08-11 SC 13D/A SC 13D/A 0001193125-22-218644 005-92480 221156646 34 228099
2022-08-09 10-Q 10-Q 0000950170-22-016035 001-40315 221148272 34 7797139 1 1
2022-08-09 8-K 8-K 2.02,9.01 0000950170-22-016015 001-40315 221148077 34 782328 1 1
2022-08-02 4 FORM 4 SUBMISSION 0001209191-22-043994 5281
2022-08-02 3 FORM 3 SUBMISSION 0001209191-22-043993 5920
2022-08-02 8-K 8-K 5.02 0001193125-22-209391 001-40315 221126904 34 149929 1 1
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034225 5371
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034180 5469
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034178 5406
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034177 5375
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034176 5404
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034171 5428
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034175 5422
2022-06-02 8-K 8-K 5.07 0001558370-22-009679 001-40315 22991456 34 181952 1 1
2022-05-10 10-Q 10-Q 0001558370-22-008103 001-40315 22909783 34 5493845 1 1
2022-05-10 8-K 8-K 2.02,9.01 0001558370-22-008096 001-40315 22909642 34 421592 1 1
2022-05-09 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-05-09 16:00:00 9999999995-22-001381 333-264616 22907166 33 1721
2022-05-05 CORRESP filename1.htm 0001193125-22-142273 6215
2022-05-04 UPLOAD filename1.pdf 0000000000-22-004911 40194
2022-05-02 S-3 S-3 0001193125-22-136897 333-264616 22882727 33 1339435
2022-04-22 DEFA14A DEFA14A 0001193125-22-115142 001-40315 22845648 34 566766
2022-04-22 DEF 14A DEF 14A 0001193125-22-115089 001-40315 22845473 34 809735
2022-04-05 3 FORM 3 SUBMISSION 0001209191-22-023348 10521
2022-03-23 S-8 S-8 0001193125-22-082845 333-263799 22763751 33 103881
2022-03-23 10-K 10-K 0001558370-22-004158 001-40315 22763631 34 9699838 1 1
2022-03-23 8-K 8-K 2.02,9.01 0001558370-22-004156 001-40315 22763537 34 625801 1 1
2022-03-07 8-K 8-K 5.02 0001193125-22-068011 001-40315 22718439 34 152653 1 1
2022-03-04 4 FORM 4 SUBMISSION 0001209191-22-016541 5504
2022-02-02 8-K 8-K 5.02 0001193125-22-025697 001-40315 22583636 34 150466 1 1
2022-01-27 SC 13D/A SC 13D/A 0001193125-22-019678 005-92480 22562931 34 63605
2022-01-26 SC 13G SC 13G 0001193125-22-018295 005-92480 22557981 34 54062
2022-01-24 4 FORM 4 SUBMISSION 0001209191-22-004627 5325
2022-01-24 3 FORM 3 SUBMISSION 0001209191-22-004624 5976
2022-01-24 8-K 8-K 5.02 0001193125-22-016015 001-40315 22549362 34 151656 1 1
2021-12-27 8-K 8-K 5.02 0001193125-21-367001 001-40315 211520411 34 152188 1 1
2021-12-14 4 FORM 4 SUBMISSION 0001209191-21-069448 7381
2021-12-14 4 FORM 4 SUBMISSION 0001209191-21-069443 7336
2021-12-14 4 FORM 4 SUBMISSION 0001209191-21-069439 7223
2021-12-14 4 FORM 4 SUBMISSION 0001209191-21-069436 7397
2021-11-15 4 FORM 4 SUBMISSION 0001209191-21-064587 7150
2021-11-12 10-Q 10-Q 0001558370-21-015674 001-40315 211400277 34 6856726 1 1
2021-11-12 8-K 8-K 2.02,9.01 0001558370-21-015672 001-40315 211400214 34 363892 1 1
2021-10-14 3 FORM 3 SUBMISSION 0001209191-21-060474 6026
2021-10-12 8-K 8-K 5.02 0001193125-21-296205 001-40315 211316661 34 156517 1 1
2021-08-26 4 FORM 4 SUBMISSION 0001209191-21-053523 4980
2021-08-26 4 FORM 4 SUBMISSION 0001209191-21-053522 4524
2021-08-26 4 FORM 4 SUBMISSION 0001209191-21-053520 5000
2021-08-11 8-K 8-K 7.01,9.01 0001558370-21-011217 001-40315 211161928 34 3332081 1 1
2021-08-11 10-Q 10-Q 0001558370-21-011213 001-40315 211161897 34 5760317 1 1
2021-08-11 8-K 8-K 2.02,9.01 0001558370-21-011209 001-40315 211161835 34 403845 1 1
2021-07-15 4 FORM 4 SUBMISSION 0001209191-21-046803 6187
2021-07-15 4 FORM 4 SUBMISSION 0001209191-21-046802 5240
2021-07-09 4 FORM 4 SUBMISSION 0001209191-21-046254 6786
2021-06-25 4 xslF345X03/reneo_fm4jun232021.xml 0000905718-21-000834 6705
2021-06-23 4 xslF345X03/reneo_fm4jun212021.xml 0000905718-21-000816 8931
2021-06-10 4 xslF345X03/reneo_fm4jun82021.xml 0000905718-21-000770 6704
2021-06-07 4 xslF345X03/reneo_fm4jun32021.xml 0000905718-21-000760 8930
2021-06-02 4 xslF345X03/reneo_fm4may282021.xml 0000905718-21-000744 6175
2021-05-28 4 xslF345X03/reneo_fm4may262021.xml 0000905718-21-000738 8932
2021-05-26 4/A FORM 4/A SUBMISSION 0001209191-21-036015 4448
2021-05-20 10-Q 10-Q 0001558370-21-007568 001-40315 21942336 34 5018367 1 1
2021-05-20 8-K 8-K 2.02,9.01 0001558370-21-007566 001-40315 21942321 34 371812 1 1
2021-05-14 8-K 8-K 5.02 0001193125-21-161994 001-40315 21924528 34 17138
2021-04-23 SC 13D NEW ENTERPRISE ASSOCIATES 15, L.P. / RENEO PHARMACEUTICALS, INC. -- SCHEDULE 13D 0001072613-21-000379 005-92480 21846805 34 360485
2021-04-20 SC 13D SC 13D 0000905718-21-000606 005-92480 21837926 34 72519
2021-04-19 SC 13D SC 13D 0001193125-21-120962 005-92480 21834015 34 310416
2021-04-15 4 FORM 4 SUBMISSION 0001209191-21-026862 23391
2021-04-15 4 FORM 4 SUBMISSION 0001209191-21-026826 14047
2021-04-15 4 FORM 4 SUBMISSION 0001209191-21-026823 10529
2021-04-15 3/A FORM 3/A SUBMISSION 0001209191-21-026820 4067
2021-04-15 4 FORM 4 SUBMISSION 0001209191-21-026817 8407
2021-04-14 4 FORM 4 SUBMISSION 0001209191-21-026667 9437
2021-04-14 SC 13D SC 13D 0001193125-21-116375 005-92480 21826146 34 121161
2021-04-13 4 FORM 4 SUBMISSION 0000899243-21-015634 19229
2021-04-13 8-K 8-K 5.03,8.01,9.01 0001193125-21-114744 001-40315 21823434 34 168805
2021-04-12 4 FORM 4 SUBMISSION 0001209191-21-026343 5167
2021-04-12 4 FORM 4 SUBMISSION 0001209191-21-026340 5222
2021-04-12 4 FORM 4 SUBMISSION 0001209191-21-026339 5178
2021-04-12 4 FORM 4 SUBMISSION 0001209191-21-026338 5228
2021-04-12 4 FORM 4 SUBMISSION 0001209191-21-026337 5269
2021-04-12 4 FORM 4 SUBMISSION 0001209191-21-026336 5204
2021-04-12 4 FORM 4 SUBMISSION 0001209191-21-026335 5214
2021-04-09 424B4 424B4 0001193125-21-111652 333-254534 21818288 33 3947894
2021-04-09 S-8 S-8 0001193125-21-110620 333-255140 21816309 33 357929
2021-04-08 SEC STAFF LETTER filename1.pdf 9999999997-21-001620 275639
2021-04-08 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2021-04-08 16:00:00 9999999995-21-001364 333-254534 21816394 33 1679
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026130 5041
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026124 2842
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026123 16183
2021-04-08 3 FORM 3 SUBMISSION 0000899243-21-015406 12483
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026110 5939
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026107 11608
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026103 5907
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026099 8616
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026095 9027
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026094 7013
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026092 5892
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026090 12367
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026089 6985
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026088 6934
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026085 9699
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026082 7055
2021-04-08 3 FORM 3 SUBMISSION 0001209191-21-026080 7972
2021-04-08 CERT 8A_Cert_RPHM.pdf 0001354457-21-000457 001-40315 21814840 34 192819
2021-04-06 8-A12B 8-A12B 0001193125-21-107604 001-40315 21809386 34 13665
2021-04-06 CORRESP filename1.htm 0001193125-21-107482 10311
2021-04-06 CORRESP filename1.htm 0001193125-21-107478 8734
2021-04-05 S-1/A S-1/A 0001193125-21-105697 333-254534 21803914 33 5875162
2021-03-22 SEC STAFF LETTER filename1.pdf 9999999997-21-001724 272600
2021-03-19 CORRESP filename1.htm 0001193125-21-087749 37646

Latest XBRL company facts

One latest value per concept from companyfacts (251 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 40.50M 2026-11-02 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
dei EntityPublicFloat Entity Public Float USD 28.00M 2025-06-30 2025 FY 10-K 2026-03-12 0001193125-26-104147
ffd NetFeeAmt NetFeeAmt USD 24,308.94 2026-04-24 S-3 2026-04-24 0001193125-26-177093
ffd TtlFeeAmt TtlFeeAmt USD 24,308.94 2026-04-24 S-3 2026-04-24 0001193125-26-177093
ffd TtlOfferingAmt TtlOfferingAmt USD 176.02M 2026-04-24 S-3 2026-04-24 0001193125-26-177093
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-04-24 S-3 2026-04-24 0001193125-26-177093
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-04-24 S-3 2026-04-24 0001193125-26-177093
us-gaap AccountsPayableAndOtherAccruedLiabilitiesCurrent Accounts Payable and Other Accrued Liabilities, Current USD 6.23M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 2.31M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 88,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 4.66M 2025-06-30 2025 Q2 10-Q 2025-08-12 0001193125-25-178981
us-gaap AccruedSalariesCurrent Accrued Salaries, Current USD 1.22M 2022-03-31 2022 Q1 10-Q 2022-05-10 0001558370-22-008103
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 1.66M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -30,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 420.35M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 3.49M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 138,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 9.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AmortizationOfFinancingCosts Amortization of Debt Issuance Costs USD 142,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 6.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AreaOfRealEstateProperty Area of Real Estate Property sqft 14,790 2026-03-31 2026 Q1 10-Q 2026-05-05 0001193125-26-206345
us-gaap Assets Assets USD 167.08M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AssetsCurrent Assets, Current USD 165.59M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 89.56M 2021-03-31 2021 Q1 10-Q 2021-05-20 0001558370-21-007568
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 2,000 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 0 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 11.89M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One USD 11.89M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 11.86M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 11.86M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 11.86M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets USD 65.50M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents USD 57.74M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities USD 15.98M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other USD 690,000 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other USD 9.07M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets USD 553,000 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 11,000 2023-01-01 2023-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 151.44M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 163.30M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 151.44M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 92.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 3.79M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 210.00M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 3.34M 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 3.34M 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap CommonStockValue Common Stock, Value, Issued USD 0 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -48.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure USD 250,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ConversionOfStockAmountIssued1 Conversion of Stock, Amount Issued USD 23.31M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain (Loss), before Tax USD 0 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054452
us-gaap DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-sale, Realized Gain (Loss) USD -54,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredCompensationArrangementWithIndividualCompensationExpense Deferred Compensation Arrangement with Individual, Compensation Expense USD 326,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredCompensationLiabilityClassifiedNoncurrent Deferred Compensation Liability, Classified, Noncurrent USD 0 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 400,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 167,000 2021-12-31 2021 FY 10-K 2022-03-23 0001558370-22-004158
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 7.00M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 123.99M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 36.09M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 0 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 58.18M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration USD 800,000 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 91,000 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredTaxAssetsPropertyPlantAndEquipment Deferred Tax Assets, Property, Plant and Equipment USD 89,000 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 6.11M 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 19.36M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits USD 1.89M 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 2.42M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals USD 840,000 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other USD 35,000 2021-12-31 2022 FY 10-K 2023-03-27 0000950170-23-009978
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 123.99M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DeferredTaxLiabilitiesLeasingArrangements Deferred Tax Liabilities, Leasing Arrangements USD 126,000 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 9,000 2020-12-31 2021 FY 10-K 2022-03-23 0001558370-22-004158
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 483,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 200,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent pure 0.04 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 244,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap DepreciationExpenseOnReclassifiedAssets Depreciation Expense on Reclassified Assets USD 244 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap Dividends Dividends USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -1.27 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -1.82 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0001558370-21-015674
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -1.27 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.454 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure -0.001 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap EffectiveIncomeTaxRateReconciliationGiltiPercent EffectiveIncomeTaxRateReconciliationGiltiPercent pure 0.004 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure 0.018 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-23 0001558370-22-004158
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.015 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0.225 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.034 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure 0.025 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 2.67M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 2.80M 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 USD 0 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 USD 0 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 USD 0 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 USD 0 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements USD -590,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-23 0001558370-22-004158
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value USD 57,000 2022-03-31 2022 Q1 10-Q 2022-05-10 0001558370-22-008103
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD -300,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-23 0001558370-22-004158
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD -54,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD -2,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 12.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ImpairmentOfInvestments Other than Temporary Impairment Losses, Investments USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-27 0000950170-23-009978
us-gaap ImpairmentOfLeasehold Impairment of Leasehold USD 400,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -78.13M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -77.39M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 744,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap IncomeTaxesPaid Income Taxes Paid USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncomeTaxExaminationPenaltiesAndInterestAccrued Income Tax Examination, Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 27.03M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD -39,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -12.50M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 3,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 917,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD -13.41M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -2.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD 3.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -412,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap IncreaseDecreaseInOtherNoncurrentLiabilities Increase (Decrease) in Other Noncurrent Liabilities USD 40,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD 131,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-27 0000950170-23-009978
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 635,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap InterestIncomeExpenseNet Interest Income (Expense), Net USD 3.52M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap InterestIncomeOperating Interest Income, Operating USD 3.52M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 907,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 255,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 34,000 2022-12-31 2022 FY 10-K 2023-03-27 0000950170-23-009978
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 34,000 2023-09-30 2023 Q3 10-Q 2023-11-13 0000950170-23-062910
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 270,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 262,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 120,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 117,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap Liabilities Liabilities USD 9.34M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 167.08M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap LiabilitiesCurrent Liabilities, Current USD 8.79M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap MarketableSecurities Marketable Securities USD 0 2025-12-31 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 140.61M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -11.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -36.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -48.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OperatingExpenses Operating Expenses USD 51.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -51.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OperatingLeaseCost Operating Lease, Cost USD 148,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 214,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap OperatingLeaseImpairmentLoss Operating Lease, Impairment Loss USD 300,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 790,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 251,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 539,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OperatingLeasePayments Operating Lease, Payments USD 440,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 661,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 379,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.092 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 617,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 409,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -30,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -17,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 12,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap OtherNonoperatingIncome Other Nonoperating Income USD 48,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-23 0001558370-22-004158
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 3.11M 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap OtherPrepaidExpenseCurrent Other Prepaid Expense, Current USD 1.55M 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap PaymentsForRent Payments for Rent USD 183,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 4.40M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap PaymentsForRepurchaseOfPreferredStockAndPreferenceStock Payments for Repurchase of Preferred Stock and Preference Stock USD 723,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap PaymentsForRepurchaseOfPrivatePlacement Payments for Repurchase of Private Placement USD 89,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 37,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 67.75M 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 12.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 40,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap PreferredStockLiquidationPreferenceValue Preferred Stock, Liquidation Preference, Value USD 195.80M 2023-12-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap PreferredStockValueOutstanding Preferred Stock, Value, Outstanding USD 53.80M 2023-03-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 2.29M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 2.24M 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap PrepaidInsurance Prepaid Insurance USD 537,000 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap ProceedsFromConvertibleDebt Proceeds from Convertible Debt USD 6.00M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 84.61M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-27 0000950170-23-009978
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 1.01M 2023-01-01 2023-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054452
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 53.78M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 4.67M 2023-01-01 2023-06-30 2024 Q2 10-Q 2024-08-13 0000950170-24-096411
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 25,000 2024-01-01 2024-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-269540
us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale USD 15.90M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 1.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ProceedsFromSaleOfInterestInCorporateUnit Proceeds from Sale of Interest in Corporate Unit USD 57.74M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 26,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 203,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 2.08M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 414,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 39.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -262.59M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap Revenues Revenues USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-10 0000950170-25-036252
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 653,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap SeveranceCosts1 Severance Costs USD 0 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-269540
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 9.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost Share-based Payment Arrangement, Accelerated Cost USD 300,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0001558370-21-015674
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 1.301 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.043 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 13,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 1.75M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 16.02 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 418,000 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-11 0001558370-21-011213
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 40,530 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 62,996 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 106,632 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 2.74M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 3.59 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0001558370-21-015674
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 14,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 5.31M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 9.79 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 15,000 2025-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-269540
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 2.71M 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 15.54 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 360,725 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value USD/shares 50.2 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price USD/shares 14.85 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 8.25 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 4.11 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap SharePrice Share Price USD/shares 6.36 2021-03-31 2021 Q1 10-Q 2021-05-20 0001558370-21-007568
us-gaap ShortTermInvestments Short-term Investments USD 15.98M 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 157.74M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.224 2021-04-05 2022 Q3 10-Q 2022-11-08 0000950170-22-023250
us-gaap StockIssuedDuringPeriodSharesShareBasedCompensation Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture shares 70,663 2021-01-01 2021-03-31 2022 Q3 10-Q 2022-11-08 0000950170-22-023250
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 129.82M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 203,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 65.50M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap StockIssuedDuringPeriodValueShareBasedCompensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture USD 173,000 2023-07-01 2023-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123233
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 26,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2022-03-31 2022 Q1 10-Q 2022-05-10 0001558370-22-008103
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2025-12-31 2025 FY 10-K 2026-03-12 0001193125-26-104147
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 4.33M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 11.00M 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-038009
us-gaap VariableLeaseCost Variable Lease, Cost USD 128,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 37.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 16.03M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0001558370-21-015674
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 37.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-447202

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →